BrainsWay to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 – BrainsWay (NASDAQ: BWAY) announced that CEO Christopher von Jako will present at two investment conferences in September. The first is the Oppenheimer & Co. Fall Healthcare Life Sciences & Medtech Virtual Summit from September 20-23, with a presentation on September 22 at 3:45 PM ET. The second is the Cantor Fitzgerald Global Healthcare Conference from September 27-30, with a presentation on September 27 at 3:20 PM ET. Investors can arrange meetings with management during these events.

BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at two investment conferences during the month of September, as follows:

Event: Oppenheimer & Co. Fall Healthcare Life Sciences & Medtech Virtual Summit
Date: September 20-23, 2021
Presentation: September 22, 2021 at 3:45pm ET

Event: Cantor Fitzgerald Global Healthcare Conference
Date: September 27-30, 2021
Presentation: September 27, 2021 at 3:20 pm ET

Management will also meet with investors throughout these events. Investors interested in meeting with the BrainsWay management team during these events should contact their respective representatives.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com 

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com        

FAQ

When is the Oppenheimer & Co. Fall Healthcare Summit for BWAY?

The Oppenheimer & Co. Fall Healthcare Life Sciences & Medtech Virtual Summit will take place from September 20-23, 2021, with a presentation by BWAY on September 22 at 3:45 PM ET.

What is the schedule for the Cantor Fitzgerald Conference for BWAY?

The Cantor Fitzgerald Global Healthcare Conference is set for September 27-30, 2021, with BrainsWay's presentation on September 27 at 3:20 PM ET.

Who is presenting for BrainsWay (BWAY) at the conferences?

Christopher von Jako, Ph.D., the President and CEO of BrainsWay, will be presenting at both conferences.

What advancements does BrainsWay (BWAY) focus on?

BrainsWay is a leader in noninvasive neurostimulation treatments, particularly using Deep Transcranial Magnetic Stimulation for various mental health disorders.

How can investors contact BrainsWay during the conferences?

Investors interested in meeting with BrainsWay management during the conferences should reach out to their respective representatives.